Neuraxis, Inc. Common Stock (NRXS)
Healthcare › Electromedical & Electrotherapeutic Apparatus
Price History
Feb 9, 2026 — May 24, 2026Investment Snapshot
- P/B of 15.90 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -136.6%
- Revenue growing at 33% annually
Neuraxis, Inc. Common Stock (NRXS) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the AMEX , with a market capitalisation of $91 million . Key value metrics: P/B ratio 15.90, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Neuraxis, Inc. Common Stock — Fundamental Analysis Summary
On financial health, NRXS shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -136.6% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.02.
StockPik's composite Value Score for NRXS is 37/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NRXS reports a high gross margin of 84.8% (sector average: 40.1%) and a negative operating margin of -186.6%.
NRXS shows revenue growing at 33% year-over-year, with earnings growing at 5%.